Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Stock picking may pay off in certain market conditions and for investors with time and expertise. Learn factors to consider before deviating from index funds.
26,454 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
NVIDIA is set to report quarterly results as investors wrestle with hype around AI. Analysts forecast strong growth b...
Investors eye the Fennec Q1 2026 call to gauge milestones, cash runway, and potential catalysts. This guide breaks do...
Investors watched Alphabet slide as news of AI talent exits raised questions about leadership and the pace of AI inve...
Novartis faces a nuanced path in 2026, balancing new therapies with cost discipline. This guide breaks down the key d...
The YieldMax NVDA Option Income Strategy ETF has drawn attention for its high advertised yield, but market dynamics a...
Palantir has wowed investors with AI-enabled results, but its sky-high valuation raises questions. This guide uses hi...
As AI use expands from training to real-world deployment, memory players like Micron face a pivotal moment. This arti...
Nvidia is not just riding the AI wave—it's shaping it. This article explains why trillion reasons nvidia phenomenal, ...
Micron Technology soared 326% in just 12 months, but a sky-high gain doesn’t guarantee a smart buy. This guide breaks...
A surge of optimism surrounds NVIDIA's latest driverless advances and what they mean for Uber stock investors. This p...
Palantir’s latest quarter delivered impressive numbers, but the stock asks for more than strong growth. This guide br...